Get to know our clinical trials
A global randomized trial comparing pulsed-field ablation of pulmonary veins using extra-PV sources with electrographic flow mapping versus posterior-wall pulmonary veins in patients with atrial fibrillation.
THE PURPOSE OF THIS STUDY IS TO GATHER MORE INFORMATION ABOUT THE SAFETY AND EFFECTIVENESS OF THE FARAPULSE® PULSED-FIELD ABLATION SYSTEM, THE OPTIMAP® CATHETER, AND THE OPTIMAP® SYSTEM IN THE TREATMENT OF PERSISTENT ATRIAL FIBRILLATION. THIS STUDY IS INTENDED FOR PEOPLE WHO HAVE SYMPTOMS, HAVE NOT PREVIOUSLY UNDERGONE ABLATION FOR ATRIAL FIBRILLATION, AND HAVE NOT RESPONDED TO MEDICATION.
Technical Summary
- A GLOBAL RANDOMIZED TRIAL COMPARING PULSED-FIELD ABLATION OF PULMONARY VEINS USING EXTRA-PV SOURCES WITH ELECTROGRAPHIC FLOW MAPPING VERSUS POSTERIOR-WALL PULMONARY VEINS IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION (OPTIMIZE PF334).
- Code EudraCT: -
- Protocol number: PF334
- Promoter: Boston scientific
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.